Lancet
-
We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. ⋯ UK Research and Innovation (Medical Research Council) and National Institute of Health Research.